Bird flu (avian influenza) is caused by influenza A viruses that primarily infect birds but can occasionally infect humans and other animals, sometimes causing severe respiratory illness.
A phase 3 trial of an mRNA H5N1 bird flu vaccine is recruiting 4,000 volunteers in the UK and US. The Moderna-sponsored study aims to assess immune responses against emerging strains as the virus continues to evolve in mammals.
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
Moderna partners with Recordati on propionic acidemia therapy for up to $160 million, while FDA Commissioner defends mRNA vaccine support following funding cuts and regulatory challenges.
The FDA has reversed its earlier refusal and will now review Moderna's mRNA-based flu vaccine application, with a decision expected by August 5. The company modified its regulatory approach to address concerns about older adults.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01675284 |
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine |
COMPLETED | PHASE1 |
| NCT01335347 |
Safety Study of an Oral Vaccine to Prevent Avian Influenza |
COMPLETED | PHASE1 |
| NCT01006798 |
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 |
COMPLETED | PHASE1 |
